À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾

ÌõÄ¿µÄ

FDA×ÉѯίԱ»áÒ»ÖÂͶƱȷÈÏLEQEMBI?£¨lecanemab-irmb£©ÖÎÁÆ°¢¶û´Äº£Ä¬²¡µÄÁÙ´²»ñÒæ

ÖÜΧºÍÖÐÊàÉñ¾­ÏµÍ³Ò©Îï×ÉѯίԱ»á»ùÓÚÔçÆÚ°¢¶û´Äº£Ä¬²¡»¼ÕߵĴóÐÍÈ«ÇòÑéÖ¤ÐÔIIIÆÚClarity ADÁÙ´²ÊÔÑéµÄÊý¾Ý½øÐбí¾ö ¡£
×÷ΪÓÅÏÈÉóÆÀ £¬LEQEMBI´«Í³ÉóÅúPDUFAÐж¯ÈÕÆÚÒѶ¨ÔÚ2023Äê7ÔÂ6ÈÕ ¡£
LEQEMBIÓÚ2023Äê1ÔÂ6ÈÕÔÚÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö¿ìËÙͨµÀÈ϶¨Ï»ñµÃÅú×¼ £¬ÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡ ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§Ë³Àûͨ¹ýÄÜÔ´¹ÜÀíÌåϵÈÏÖ¤

¾­ÖйúÖÊÁ¿ÈÏÖ¤ÖÐÐĵÄÉóºË £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ËÕÖݹ¤³§£¨ÒÔϼò³ÆÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§£©Ë³Àûͨ¹ýÁËGB/T23331-2020/ISO50001:2018ÄÜÔ´¹ÜÀíÌåϵÈÏÖ¤²¢È¡µÃÖ¤Êé £¬±êÖ¾×ÅÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§ÄÜÔ´¹ÜÀíÌåϵ½¨ÉèÒÔ¼°Éú²ú½ÚÄܹÜÀíÔÚ¿Æѧ»¯¡¢¾«Ò滯¡¢³ß¶È»¯·½ÃæÈ¡µÃÁËÏÔÖø³ÉЧ ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚµÚ37½ìÃÀ¹úÁªºÏרҵ˯Ãßѧ»áÉϽéÉÜLemborexantµÄ×îÐÂÊý¾Ý

2023Äê6ÔÂ3ÈÕÖÁ7ÈÕ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚÃÀ¹úÓ¡µÚ°²Äɲ¨Àû˹¾ÙÐеĵÚ37½ìÃÀ¹úÁªºÏרҵ˯Ãßѧ»á£¨SLEEP 2023£©Äê»áÉÏÐû²¼8·Ý³ÂËß £¬°üÂÞÆäÔ­ÑеÄʳÓûËØÊÜÌåÞ׿¹¼ÁLemborexant£¨²úÎïÃû³Æ£ºDAYVIGO?£©µÄ×îÐÂÊý¾Ý ¡£

ÀÖÎÀÂê?£¨ÂØ·¥ÌæÄᣩÓë¿ÉÈð´ï?£¨ÅÁ²©ÀûÖéµ¥¿¹£©ÁªºÏÓÃÒ©×÷ΪÍíÆÚÉöϸ°û°©»¼ÕßµÄÒ»ÏßÖÎÁÆ £¬ÓëÊæÄáÌæÄáÏà±ÈÏÔʾ³öÉú´æÆÚºã¾Ã³Ö¾ÃµÄÓÅÊÆ

¾­¹ýËÄÄêµÄËæ·Ã £¬ÔÚÒªº¦ÐÔIIIÆÚCLEAR£¨Ñо¿307£©/KEYNOTE-581ÊÔÑéÖÐ £¬ÀÖÎÀÂêÁªºÏ¿ÉÈð´ïÓëÊæÄáÌæÄáÏà±È £¬ËÀÍö·çÏÕ½µµÍ21% ¡£
×îÖÕ½á¹û½«ÔÚ2023ÄêµÄASCO»áÒéÉÏÒÔ¿ÚÍ·ÕªÒªµÄÐÎʽ½øÐз¢±í ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«»ý¼«Îª±»ºöÊÓµÄÈÈ´ø²¡ºÍű¼²¿ª·¢ÐÂÒ© £¬²¢ÎªÈ«Çò½¡¿µ¼¼ÊõÕñÐË»ù½ðµÚÈý½×¶ÎÌṩ×ʽðÖ§³Ö

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÌåÏÖ £¬½«Ïò¹«ÒæÉçÍÅ·¨ÈËÈ«Çò½¡¿µ¼¼ÊõÕñÐË»ù½ð£¨Global Health Innovative Technology Fund£©ÎªÆÚÎåÄ꣨×Ô2023ÄêÖÁ2027Ä꣩×ܼÆ6.25ÒÚÈÕÔªµÄµÚÈýÆÚ»ù½ð ¡£GHIT Fund½¨Á¢ÓÚ2013Äê4Ô £¬ÓÉ°üÂÞÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚÄÚµÄÈÕ±¾ÖÆÒ©ÆóÒµ¡¢ÈÕ±¾¹úÕþ¸®¡¢±È¶ûºÍ÷Áմ¸Ç´Ä²ÆÍŵȺÏ×÷»ï°éÅäºÏÉèÁ¢ £¬Ö¼ÔÚ´Ù½øÈÕ±¾ºÍº£ÍâÑо¿»ú¹¹µÄºÏ×÷ £¬¼ÓËÙÑз¢Õë¶ÔÉú³¤Öйú¼ÒºÍÐÂÐ˹ú¼ÒµÄѬȾ²¡µÄ´´ÐÂÒ©Îï ¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒÑÏòGHIT FundÌṩµÚÒ»ÆÚ£¨2013 – 2017Äê¶È£©ºÍµÚ¶þÆÚ£¨2018 – 2022Äê¶È£©»ù½ð¹²¼Æ10ÒÚÈÕÔªµÄ×ʽðÖ§³Ö ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚASCO 2023ÉÏÐû²¼×îÐÂÖ×ÁöÑз¢¹ÜÏßÏà¹ØÊý¾ÝºÍ½øÕ¹Çé¿ö

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçÐû²¼ £¬½«ÔÚ6ÔÂ2ÈÕÖÁ6ÈÕÃÀ¹úÒÁÀûŵÒÁÖÝÖ¥¼Ó¸ç¾ÙÐеÄ2023ÄêÃÀ¹úÁÙ´²Ö×Áöѧ»á£¨ASCO£©Äê»á£¨#ASCO23£©ÉÏ £¬Õ¹Ê¾ÆäÖÖÖÖÐÍÖ×ÁöÑз¢¹ÜÏßµÄÑо¿½øÕ¹Çé¿ö ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚÓ¢¹úÌá½»LecanemabÉÏÊÐÐí¿ÉÉêÇë

5ÔÂ22ÈÕ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒÑÏòÓ¢¹úÒ½Ò©ºÍ½¡¿µ²úÎï¹ÜÀí¾Ö£¨MHRA£©Ìá½»ÁËLecanemabµÄÉÏÊÐÐí¿ÉÉêÇ루MAA£© ¡£LecanemabÊÇÒ»ÖÖʵÑéÐÔ¿¹µí·ÛÑùÂѰצ£¨A¦Â£©Ô­ÏËά¿¹Ìå £¬ÓÃÓÚÖÎÁÆ´óÄÔÖÐÈ·ÈÏ´æÔÚµí·ÛÑùÂѰײ¡ÀíµÄÔçÆÚ°¢¶û´Äº£Ä¬² ¡£¨AD£©ºÍÇá¶ÈADÒýÆðµÄÈÏÖªÕÏ°­ ¡£LecanemabÒѱ»MHRAÖ¸¶¨ÎªILAP* ¡£

ÎÀ¿ËÌ©¿Ú·þ»ìÐüÒº»ñµÃ¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÅú×¼

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ô­Ñп¹ñ²ðïÒ©Îï(ASM) ÎÀ¿ËÌ©?£¨Ó¢ÎÄÃû£ºFycompa? £¬Í¨ÓÃÃû£ºßÁÂØÅÁÄΣ©ÔÚÖйú»ñÅú¿Ú·þ»ìÐüÒº¼ÁÐÍ £¬ÓÃÓÚ³ÉÈ˺Í4Ëê¼°ÒÔÉ϶ùͯñ²ðﲿÃÅÐÔ·¢×÷»¼Õߣ¨°éÓлò²»°éÓм̷¢È«ÃæÐÔ·¢×÷£©µÄÖÎÁÆ ¡£

¼ÓÄôóÎÀÉú²¿½ÓÊÜÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÐÂÒ©LecanemabµÄÉêÇë

5ÔÂ16ÈÕ £¬¼ÓÄôóÎÀÉú²¿ÒѾ­½ÓÊÜÁËLecanemabµÄÐÂÒ©ÉêÇ루NDS£© ¡£ LecanemabÊÇÒ»ÖÖʵÑéÐÔ¿¹µí·ÛÑùÂѰצ£¨A¦Â£©Ô­ÏËά*¿¹Ìå £¬ÓÃÓÚÖÎÁƾßÓÐÄÔ²¿µí·ÛÑùÂѰײ¡ÀíµÄÔçÆÚ°¢¶û´Äº£Ä¬² ¡£¨AD£©¡ª¡ª°üÂÞÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍÇá¶ÈAD ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú×ܲ÷ëÑÞ»ÔÒ»ÐзÃÎʹú¿ØºÓÄÏ

5ÔÂ11ÈÕÉÏÎç £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú×ܲ÷ëÑÞ»ÔÝ°ÁÙ¹ú¿ØºÓÄϵ÷ÑÐÖ¸µ¼ÊÂÇé £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú¸±×ܲÃÀîÔÆÁú¡¢À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú±±Öйú×¼È벿²¿³¤ÕÔ½¨¾ý¡¢À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú×¼Èë¹ÜÀí±¾²¿ÖÐÇø´óÇø¾­ÀíÏÄÈðÓ¢µÈÅãͬ ¡£¹úÒ©¿Ø¹É¸±×ܲᢹú¿ØºÓÄ϶­Ê³¤³ÂÕ½Óî¡¢¹ú¿ØºÓÄÏ×ܾ­ÀíÕÅÕÙ»Ô¡¢¹úÒ©¿Ø¹ÉÈ«²ÉÖÐÐĸ±×ܾ­ÀíÐ캣¡¢¹ú¿ØºÓÄÏ×ܾ­ÀíÖúÀíÀî½Ü £¬¹úÒ©¿Ø¹É¹©Ó¦Á´ÒµÎñÉú³¤²¿²¿³¤Ñî·«µÈ½Ó´ýÁË·ëÑÞ»ÔÒ»ÐÐ ¡£

ÍøÕ¾µØͼ